α-synuclein (α-syn) assembles into structurally distinct fibril polymorphs seen in different synucleinopathies, such as Parkinson’s disease and multiple system atrophy. Targeting these unique fibril structures using chemical ligands holds diagnostic significance for different disease subtypes. However, the molecular mechanisms governing small molecules interacting with different fibril polymorphs remain unclear. Here, we investigated the interactions of small molecules belonging to four distinct scaffolds, with different α-syn fibril polymorphs. Using cryo-electron microscopy, we determined the structures of these molecules when bound to the fibrils formed by E46K mutant α-syn and compared them to those bound with wild-type α-syn fibrils. Notably, we observed that these ligands exhibit remarkable binding adaptability, as they engage distinct binding sites across different fibril polymorphs. While the molecular scaffold primarily steered the binding locations and geometries on specific sites, the conjugated functional groups further refined this adaptable binding by fine-tuning the geometries and binding sites. Overall, our finding elucidates the adaptability of small molecules binding to different fibril structures, which sheds light on the diagnostic tracer and drug developments tailored to specific pathological fibril polymorphs.
α‐Syn fibrils, a key pathological hallmark of Parkinson's disease, is closely associated with disease initiation and progression. Several small molecules are found to bind or dissolve α‐syn fibrils, offering potential therapeutic applications. Here, an innovative optical tweezers‐based, fluorescence‐combined approach is developed to probe the mechanical characteristics of α‐syn fibrils at the single‐molecule level. When subjected to axial stretching, local deformation within α‐syn fibrils appeared at forces above 50 pN. These structural alternations occurred stepwise and are irreversible, suggesting unfolding of individual α‐syn molecules or subdomains. Additionally, α‐syn fibrils exhibits high heterogeneity in lateral disruption, with rupture force ranging from 50 to 500 pN. The impact of different compounds on the structure and mechanical features of α‐syn fibrils is further examined. Notably, epigallocatechin gallate (EGCG) generally attenuates the rupture force of fibrils by wedging into the N‐terminal polar groove and induces fibril dissociation. Conversely, copper chlorophyllin A (CCA) attaches to four different sites wrapping around the fibril core, reinforcing the stability of the fibril against rupture forces. The work offers an effective method for characterizing single‐fibril properties and bridges compound‐induced structural alternations with mechanical response. These insights are valuable for understanding amyloid fibril mechanics and their regulation by small molecules.
20 January 2026 in Journal of the American Chemical Society
Pathological aggregation of transactive response DNA binding protein of 43 kDa (TDP-43), primarily driven by its low-complexity domain, is closely associated with various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Despite the therapeutic potential of preventing TDP-43 aggregation, no effective small molecule or biomacromolecule therapeutics have been successfully developed so far. Here, we introduce a protein design strategy that yields de novo designed proteins capable of stabilizing the key amyloidogenic region of TDP-43 in its native helical conformation with nanomolar binding affinity. The binding mechanism was further characterized by the NMR and mutagenesis study. More importantly, we demonstrated that our designed protein binders efficiently reduced TDP-43 amyloid aggregation both in vitro and in cells. Our work provides a strategy for designing protein stabilizer of the native conformation of pathological proteins for preventing its amyloid aggregation, shedding light on the development of potential therapeutic approaches for ALS, FTLD, and other protein aggregation-associated diseases.
The prion-like propagation and accumulation of pathogenic α-synuclein (α-syn) aggregates in the central nervous system are central drivers of Parkinson’s disease (PD) and related synucleinopathies, and remain an important therapeutic target. However, most reported anti-fibrillogenesis agents show limited efficacy in cells or in vivo, and their mechanisms are often poorly defined. Here, we report the unexpected finding that Pittsburgh compound B (PiB), the first clinically used amyloid tracer, selectively suppresses α-syn aggregation. Using an optimized PiB analog, HQY1027, we demonstrate that these compounds function as chemical chaperones. By directly binding polymorphic α-syn fibrils, they remodel the fibril surface and enhance Hsp40 recognition of fibril cores, thereby suppressing fibril formation both in vitro and in cells. HQY1027 is highly effective in neuronal models and significantly reduced α-syn aggregate propagation and motor deficits in a PD mouse model. Our findings establish a chemical chaperone strategy for targeting pathogenic α-syn and identify HQY1027 as a promising therapeutic lead for synucleinopathies. These results further highlight the potential of phenotype-based discovery and optimization of fibril-binding ligands to target intractable protein aggregates in neurodegenerative disorders.